In human myocardium, there is evidence suggesting FPR2 may traverse from its physiological sarcolemmal location into the cytoplasm in ischaemic heart disease, based on differences in FPR2 localization in donor left ventricle (LV) samples from ischaemic versus healthy myocardium (Tourki, Kain, Pullen, et al., 2020), albeit there are also marked differences in ethnicity and concomitant medication between the two cohorts. This evidence concerns the gene FPR2 and heart disorder.